These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 18640458)

  • 1. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA
    Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.
    Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D
    Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
    Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.
    Vellas B; Black R; Thal LJ; Fox NC; Daniels M; McLennan G; Tompkins C; Leibman C; Pomfret M; Grundman M;
    Curr Alzheimer Res; 2009 Apr; 6(2):144-51. PubMed ID: 19355849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization.
    Jäkel L; Boche D; Nicoll JAR; Verbeek MM
    Acta Neuropathol Commun; 2019 Sep; 7(1):141. PubMed ID: 31477180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
    Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML
    Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial alterations in human Alzheimer's disease following Aβ42 immunization.
    Zotova E; Holmes C; Johnston D; Neal JW; Nicoll JA; Boche D
    Neuropathol Appl Neurobiol; 2011 Aug; 37(5):513-24. PubMed ID: 21166690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of active Aβ immunotherapy on neurons in human Alzheimer's disease.
    Paquet C; Amin J; Mouton-Liger F; Nasser M; Love S; Gray F; Pickering RM; Nicoll JA; Holmes C; Hugon J; Boche D
    J Pathol; 2015 Apr; 235(5):721-30. PubMed ID: 25430817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
    Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
    J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
    Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
    J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
    Ballard C; Hanney ML; Theodoulou M; Douglas S; McShane R; Kossakowski K; Gill R; Juszczak E; Yu LM; Jacoby R;
    Lancet Neurol; 2009 Feb; 8(2):151-7. PubMed ID: 19138567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active immunization of mice with an Abeta-Hsp70 vaccine.
    Koller MF; Mohajeri MH; Huber M; Wollmer MA; Roth Z'graggen BV; Sandmeier E; Moritz E; Tracy J; Nitsch RM; Christen P
    Neurodegener Dis; 2004; 1(1):20-8. PubMed ID: 16908970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and immunogenicity of an active anti-Aβ
    Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
    Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
    Town T
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.